Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.
Fangda assists Brattea in completing its high-value series-D financing
2024 / 04 / 24
READ MORE
2026 / 06 / 24
Fangda Advises SEER TECH on Its Hong Kong 18C Listing as the “First Robot Brain Stock”
2026 / 06 / 22
Fangda Advised Insilico Medicine on AI-powered Drug Discovery Collaboration with SK Biopharmaceuticals Worth Up to USD2.5 Billion for Neuroimmune Disorders
2026 / 06 / 22
Fangda Advises Yum China on Its USD 1.2 Billion Acquisition of the Ownership of the Pizza Hut Brand in Mainland China
2026 / 06 / 08
Fangda Advises LTW Capital on the Acquisition of 100% Equity Interest in Shanghai Dacromet, a Wholly Owned Subsidiary of Wanfeng Auto Wheel
2026 / 05 / 29
Fangda Advises WuXi AppTec on the Issuance of RMB 6.78 Billion in U.S. Dollar-Settled Zero-Coupon Convertible Bonds Due 2027
